- Home
- FFIV vs RPRX Comparison
FFIV vs RPRX Comparison
Compare FFIV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FFIV | RPRX |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7B | 16.2B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FFIV | RPRX |
|---|---|---|
| Price | $247.98 | $39.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $297.22 | $46.00 |
| AVG Volume (30 Days) | 1.1M | ★ 4.3M |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | ★ 23.56 | N/A |
| EPS | ★ 11.80 | 1.75 |
| Revenue | ★ $3,088,072,000.00 | $2,349,844,000.00 |
| Revenue This Year | $3.98 | $37.13 |
| Revenue Next Year | $4.05 | $1.48 |
| P/E Ratio | ★ $21.03 | $22.68 |
| Revenue Growth | ★ 9.66 | 3.70 |
| 52 Week Low | $223.76 | $24.05 |
| 52 Week High | $346.00 | $41.24 |
Technical Indicators
Market Signals| Indicator | FFIV | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 57.50 |
| Support Level | $233.96 | $39.24 |
| Resistance Level | $243.26 | $40.50 |
| Average True Range (ATR) | 5.99 | 0.91 |
| MACD | 4.21 | -0.08 |
| Stochastic Oscillator | 95.76 | 76.02 |
Price Performance
Historical ComparisonAbout FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.